Exome chip analyses in adult attention deficit hyperactivity disorder by Zayats, T. et al.
OPEN
ORIGINAL ARTICLE
Exome chip analyses in adult attention deﬁcit hyperactivity
disorder
T Zayats1, KK Jacobsen1, R Kleppe1, CP Jacob2, S Kittel-Schneider3, M Ribasés4,5,6, JA Ramos-Quiroga4,5,6,7, V Richarte4,5,6,7, M Casas4,5,6,7,
NR Mota8, EH Grevet9, M Klein10, J Corominas10,11, J Bralten10, T Galesloot12, AA Vasquez10,13,14, S Herms15,16,17, AJ Forstner15,16,
H Larsson18, G Breen19,20, P Asherson19,20, S Gross-Lesch2, KP Lesch2, S Cichon16,17,21, MB Gabrielsen22,23, OL Holmen22, CHD Bau8,
J Buitelaar13, L Kiemeney12, SV Faraone1,24, B Cormand25,26,27,28, B Franke10,14, A Reif3, J Haavik1,29 and S Johansson30,31
Attention-deﬁcit/hyperactivity disorder (ADHD) is a highly heritable childhood-onset neuropsychiatric condition, often persisting
into adulthood. The genetic architecture of ADHD, particularly in adults, is largely unknown. We performed an exome-wide scan of
adult ADHD using the Illumina Human Exome Bead Chip, which interrogates over 250 000 common and rare variants. Participants
were recruited by the International Multicenter persistent ADHD CollaboraTion (IMpACT). Statistical analyses were divided into 3
steps: (1) gene-level analysis of rare variants (minor allele frequency (MAF)o1%); (2) single marker association tests of common
variants (MAF⩾ 1%), with replication of the top signals; and (3) pathway analyses. In total, 9365 individuals (1846 cases and 7519
controls) were examined. Replication of the most associated common variants was attempted in 9847 individuals (2077 cases and
7770 controls) using ﬁxed-effects inverse variance meta-analysis. With a Bonferroni-corrected signiﬁcance level of 1.82E− 06, our
analyses of rare coding variants revealed four study-wide signiﬁcant loci: 6q22.1 locus (P= 4.46E− 08), where NT5DC1 and COL10A1
reside; the SEC23IP locus (P= 6.47E− 07); the PSD locus (P= 7.58E− 08) and ZCCHC4 locus (P= 1.79E− 06). No genome-wide
signiﬁcant association was observed among the common variants. The strongest signal was noted at rs9325032 in PPP2R2B (odds
ratio = 0.81, P= 1.61E− 05). Taken together, our data add to the growing evidence of general signal transduction molecules
(NT5DC1, PSD, SEC23IP and ZCCHC4) having an important role in the etiology of ADHD. Although the biological implications of these
ﬁndings need to be further explored, they highlight the possible role of cellular communication as a potential core component in
the development of both adult and childhood forms of ADHD.
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INTRODUCTION
Attention-deﬁcit/hyperactivity disorder (ADHD) is the most com-
monly diagnosed childhood-onset neuropsychiatric condition,1
persisting into adulthood in up to 60% of the cases.2 The adult
form of ADHD presents a high risk for developing co-morbid
psychiatric conditions, increasing the burden of disease and,
consequently, global impairment, resistance to treatment and costs
of illness.3,4
ADHD in children and adolescents is highly heritable with an
estimated mean heritability of ~ 76%.5 Although genome-wide
association studies of ADHD show that ~ 40% of ADHD’s
heritability can be accounted for by common variants,6 no
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genome-wide signiﬁcant (Po5.00E− 08) single-nucleotide var-
iants (SNVs) have yet been identiﬁed. Meta-analyses of some
candidate genes and genome-wide association results have
yielded interesting hypotheses for this disorder, with pathway
analyses pointing towards neurodevelopmental networks.1
The mixed results of the previous association studies may be
partially due to the polygenic and multifactorial nature of ADHD,
with both common and rare variants likely contributing to its
etiology.7,8 Phenotypic heterogeneity could be another explana-
tion for the multifarious ﬁndings in ADHD genetics. Such
heterogeneity could occur when various smaller sets are
combined to increase sample size and it may lead to the loss of
a real association signal.9 Examination of a reﬁned phenotype may
reduce phenotypic heterogeneity and increase the probability of
detecting a true association signal, although adequately large
sample size will still be required to detect associations of small
effects.
Given that ADHD is a developmentally heterogeneous condi-
tion that covers both a remitting and a persistent adult type of
ADHD,1 symptom persistence may represent one promising
reﬁned phenotype.10 As most molecular genetic studies on ADHD
so far have been limited to its childhood form only, this might
constrain the possibilities to identify genetics of symptom
persistence.
In this study, we investigated the role of common and rare
exonic polymorphisms in the persistent, adult form of ADHD
(aADHD). The focus on low frequency protein-coding variants in
addition to the genome-wide common polymorphisms provides
an additional source of potentially relevant variation that has
received little attention in aADHD genetic studies so far.
MATERIALS AND METHODS
Subjects
All adult ADHD cases examined in this study were volunteers enrolled
through the International Multicenter persistent ADHD CollaboraTion
(IMpACT). All patients were diagnosed with ADHD according to DSM-IV
criteria, meaning the presence of ADHD symptoms before 7 years of age.
Controls were recruited either at an IMpACT site (Brazil, Germany, The
Netherlands, UiB Norway and Spain) or through population studies
(Germany, The Netherlands, HUNT Norway and the United Kingdom). All
subjects were of European descent who was ensured by means of self-
report together with multi-dimensional scaling (Supplementary Appendix
1). In Brazil, only Native Brazilians of European descent were recruited by
including only those who reported having grandparents of European
descent and by performing a morphological classiﬁcation based on skin
color and morphological traits rather than relying on self-classiﬁcation
only.11 The population in Southern Brazil where this study was performed
is mainly of European descent and population stratiﬁcation was not found
in the European-derived population of Rio Grande do Sul.12,13 Individuals
from Southern Brazil show predominantly European ancestry (94%)
according to estimates of interethnic admixture.13,14
All participants provided signed informed consent in accordance with
the Declaration of Helsinki. The study was approved by ethics committees
in each collaborating country at the corresponding recruitment center: in
Germany, by the Ethics Committee at the University of Würzburg
(Würzburg, Germany); in Norway, by the regional Ethics Committee for
medical and health research ethics, western Norway at the University of
Bergen (Bergen, Norway) and the Norwegian Data Inspectorate, the
Regional and National Committees for Medical and Health Research
Ethics and the Norwegian Directorate of Health at the University of
Trondheim (Trondheim, Norway); in Spain, by the Ethics Committee of the
Hospital Universitari Vall d'Hebron (HUVH, Barcelona, Spain) at the
Department of Psychiatry from the Hospital Universitari Vall d'Hebron
(HUVH, Barcelona, Spain); in the Netherlands, by the regional Ethics
Committee (Centrale Commissie Mensgebonden Onderzoek: CMO Regio
Arnhem—Nijmegen; Protocol number III.04.0403), the Institutional
Review Board of the Radboud University Medical Center (Nijmegen,
the Netherlands) and by the regional Ethics Committee (Centrale
Commissie Mensgebonden Onderzoek: CMO Regio Arnhem Nijmegen;
2008/163; ABR: NL23894.091.08) at the outpatient clinic of GGZ Delﬂand in
Delft, to Parnassia, psycho-medical centre in The Hague or at the
department of Psychiatry at the Radboud University Nijmegen
Medical Centre in Nijmegen, the Netherlands.; in Brazil, by the Ethics
Committee of the Hospital de Clínicas de Porto Alegre (Porto Alegre, Brazil)
at the ADHD Outpatient Program at the Hospital de Clínicas de Porto
Alegre (HCPA); in UK, by the National Research Ethics Committee at the
National Adult ADHD Outpatient Clinic at the South London and Maudsley
NHS Trust, (London, UK) and the Wellcome Trust Case Control Consortium
(WTCCC).
For the discovery phase of the study, samples were available from four
European IMpACT sites: Germany, The Netherlands, Norway and Spain. A
replication sample, to examine the most signiﬁcant SNVs from the
common variant analysis identiﬁed in the discovery stage, was recruited
from the following four IMpACT sites: Brazil, Germany, The Netherlands
and the UK. Additional samples were recruited through the WTCCC. A
detailed description of all samples is provided in the Supplementary
Appendix 1.
Genotyping, genotype calling and quality control
All subjects included in the discovery stage were genotyped on the
InﬁniumHumanExome array (Illumina, San Diego, CA, USA). The German
cases, the full Dutch sample and the full Spanish sample were genotyped
on HumanExome-12v1-1_A, the German controls and the HUNT Norwe-
gian sample of controls were genotyped on HumanExome-12v1_A and the
UiB Norwegian sample was genotyped on HumanExome-12v1_B version of
the chip. All genotypes were processed using the Illumina GenomeStudio
V2011.1 software, with additional genotype assignments implemented in
the zCall.15 Best practice guidelines were used to perform quality control
(QC) of genotype calls in GenomeStudio.16 Further QC was carried out on
all data sets using PLINK,17 with the following steps: (1) genotyping rate
threshold was set to 98% both for individuals and for SNVs, (2) Hardy–
Weinberg test threshold was set to Po1.00E− 05, (3) overall hetero-
zygosity of individuals was screened based on common (minor allele
frequency (MAF)⩾ 1%) and rare (MAFo1%) SNVs separately, with outliers
deﬁned as those outside the range of mean± 3s.d. of the total
heterozygosity observed in a sample, (4) relatedness (PI_HAT) threshold
was set to 10% and (5) ethnic homogeneity was ensured by means of
multi-dimensional scaling with HapMap3 populations. Genotype calling
and all QC steps were performed for each data set individually. Those
samples that were collected in the same country (namely German cases
and German controls, Dutch cases and Dutch controls, Norwegian UiB and
HUNT samples) were merged in PLINK and additional QC steps were
implemented. Speciﬁcally, the screening for heterozygosity, cryptic
relatedness and population outliers was performed once more as
described above. As the end result, four data sets were produced: a
combined German sample, a combined Dutch sample, a combined
Norwegian sample and a Spanish sample.
For the replication stage, the most signiﬁcant three common (MAF41%)
SNVs were genotyped by KASP assay (LGC Genomics, UK) in IMpACT
samples (Brazil, Germany, The Netherlands and the UK). The Dutch
replication sample was also genotyped on Perlegen (Perlegen Sciences)
and HumanCytoSNP-12 array (Illumina).
Statistical analyses
Statistical analyses were divided into three main stages: (1) examination of
rare coding SNVs (MAFo1%), (2) examination of common SNVs (MAF⩾
1%) with replication in an independent sample and (3) exploration of
biological pathways possibly involved in the development of adult ADHD
based on the results from the previous two steps. Prior to the analyses,
each subject’s genetic substructure characteristics were estimated with
principal components analysis implemented in EIGENSTRAT software for
each data set individually.18 Calculation of principal components was
performed based only on individuals and SNVs revealing high genotyping
rate (⩾99%) and common variants (MAF⩾ 1%) after removal of strand
ambiguous SNVs and those in high LD (r2o0.2). Long stretches of LD were
also removed prior to calculation of principal components.19
Examination of rare coding variants
Rare variants were deﬁned as those with MAFo1%. The variants were
combined per gene and tested for association with adult ADHD in
RAREMETAL.20 The software ﬁrst analyzes each data set individually and
then combines the generated summary statistics across all the data (meta-
analysis). The individual analyses generated single-variant score statistics
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as well as covariance matrices to reﬂect linkage disequilibrium (LD) among
the variants. We performed two meta-analyses at the gene level: the MAF-
weighted burden test and the variable threshold test (VT) across all data
sets. Only those genes were tested in which at least two variants were
observed across all data sets. All individual tests were adjusted for the
number of signiﬁcant principal components as calculated in EIGENSTRAT.
Variants of those genes that reached a P-value below 1.00E− 05 in the
individual association tests were manually evaluated in GenomeStudio in
the German, Dutch and Norwegian data sets. GenomeStudio data was not
available for the Spanish data set. Single-nucleotide polymorphisms
displaying less than optimal clustering were excluded. Bonferroni
correction was applied to adjust for multiple testing in the ﬁnal step of
the analyses.
Signiﬁcant association signals, revealed by these analyses of rare
variants, were also examined in the context of association among common
variants in meta-analysis of this study as well as in that of Psychiatric
Genomics Consortium (PGC).
Examination of common variants
Common SNVs were deﬁned as those with MAF⩾ 1%. The variants were
tested in PLINK software, assuming an additive model. Each data set was
ﬁrst analyzed separately, including signiﬁcant EIGENSTRAT principal
components as covariates. The results were then combined with the use
of ﬁxed-effects inverse variance meta-analysis in METAL,21 applying
genomic control.22 Only those SNVs present in at least two data sets
were meta-analyzed. QQ-plots were constructed to ensure proper
distribution of observed statistics.
Replication was attempted for the top three SNVs detected in the
discovery phase. In the Brazilian, Dutch and German samples, the
association of each top variant was assessed in PLINK with logistic
regression assuming an additive model. The association in the British
sample was assessed by the chi-square test after constructing 2 × 2
contingency tables of allele counts, as we did not have access to raw
genotype data of the controls. Each data set was analyzed individually. The
results were combined in the ﬁxed-effects inverse variance meta-analysis
implemented in PLINK. The three top common variants were also looked
up in the largest published ADHD genome-wide association meta-analysis
of PGC.
In silico functional analyses of the signiﬁcant loci
We performed a comprehensive assessment of all rare SNVs contributing
to the association signals that survived the study-wide correction for
multiple testing to explore their potential functional impact. Such effect
was evaluated in two ways: (1) inﬂuence of the genetic variation on the
encoded protein and (2) regulatory DNA effects (sequences which regulate
gene transcription, gene expression and/or DNA replication). The severity
of missense SNVs on the function of the encoded proteins was assessed
with sequence alignment, using protein blast and protein homology
modeling. Applying homology models of human NT5DC1, the structural
details surrounding the sites of missense mutations were investigated in
Discovery studio Visualizer (v 4.1; Illumina). In addition, SIFT and PolyPhen
predictions were also carried out in Ensembl Variant Effect Predictor (VEP).
The possible regulatory effects were assessed in RegulomeDB, utilizing
genomic annotation databases that employ the data curated by the
Encyclopedia of DNA Elements (ENCODE) and provide information on
functionally important elements. RegulomeDB identiﬁes DNA features and
regulatory elements of the human genome.23
Exploration of biological pathways: GO terms
To evaluate whether any biological processes may be implicated by our
results, we performed gene-set analyses using gene ontology (GO) terms.
The analyses were performed in MAGMA.24 First, a degree of association
was calculated for each gene based on both common and rare variants by
the use of principal component regression. Rare variants were deﬁned as
those with MAFo1% and a burden score was created for each gene,
computed as weighted sum of all rare variants in that gene. All data sets
were analyzed individually, adjusted for signiﬁcant EIGENSTRAT compo-
nents. Fixed effects meta-analysis was then performed, using the square
root of the sample sizes as weights. To evaluate each gene’s contribution
to the examined gene-sets (GO term), the P-value of each gene from the
meta-analysis was converted to a Z-value and used as an outcome variable
for a regression model with gene-set membership as a predictor. Gene
size, gene-sets’ gene density as well as global LD were added as covariates
to adjust for possible confounding effects and prevent spurious associa-
tion. We restricted our pathway analysis only to those sets that contained
SNVs in at least 10 genes in our total aADHD data (all four data sets).
Bonferroni correction was applied to adjust for multiple testing.
Gene expression in brain tissue
Gene expression in the human brain across the lifetime was assessed for
the loci surviving the Bonferroni correction. Data was accessed from the
Human Brain Transcriptome project (http://hbatlas.org), the Expression
Atlas (https://www.ebi.ac.uk/gxa/home) and Allen Brain Atlas (http://www.
brain-map.org/).
RESULTS
Subjects and genotyping
After QC, 9365 individuals (1846 adult ADHD cases and 7519
controls) were available for the analyses. Supplementary Appendix
1 and Table 1 present the details of the four discovery data sets.
Examination of rare coding variants
As it is still unknown what is the most powerful statistical
approach for testing whether a mixture of neutral, risk and
protective variants is present within a single gene,25 we leaned on
the view of rare functional variants being under selective pressure
and utilized two methods to explore such scenario: (1) the MAF-
weighted burden test that deﬁnes rare variants with a ﬁxed
threshold and places weights inverse to the MAFs of the variants
within a gene and (2) the VT that empirically determines the MAF
threshold and makes no prior assumption about the relationship
between MAFs and effect sizes of the variants within a gene. Out
of 14 431 genes with observed variants, 13 715 genes contained at
least two variants. We adjusted our signiﬁcance level for the use of
two methods and the 13 715 genes containing more than two rare
SNVs (27 430 tests in total), which yielded a Bonferroni-corrected
study-wide signiﬁcance threshold of 1.82E− 06. Four loci survived
this correction for multiple testing. The most signiﬁcant associa-
tion was observed using the VT method, present at 6q22.1
(P= 4.46E− 08, MAF threshold = 0.00027), where the 5′-nucleoti-
dase domain containing 1 (NT5DC1) gene resides along with the
collagen type X alpha 1 (COL10A1) gene. This locus was also the
most signiﬁcant ﬁnding using the MAF-weighted burden test
(ST1). Supplementary Table 2 presents details of the variants
contributing to association signal in 6q22.1 locus.
The three additional study-wide signiﬁcant associations were
observed for the SEC23 interacting protein gene (SEC23IP;
P= 6.47E− 07, VT method), the pleckstrin and Sec7 domain
containing gene (PSD; P= 7.58E− 07, MAF-weighted burden test)
Table 1. Properties of the IMpACT discovery samples examined in this
study
Individuals
IMpACT site Cases Controls Total
Germany 340 2.286 2.626
Netherlands 294 1.703 1.997
Norway 597 2.598 3.195
Spain 615 932 1.547
Total 1.846 7.519 9.365
Variants
IMpACT site Rare (MAFo1%) Common (MAF⩾ 1%) Total
Germany 71.350 33.053 104.403
Netherlands 59.415 33.336 92.751
Norway 60.649 33.870 94.519
Spain 62.559 31.564 94.123
Abbreviation: MAF, minor allele frequency.
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and zinc ﬁnger, CCHC domain containing 4 gene (ZCCHC4,
P= 1.79E− 06, VT method). ST1 summarizes the most signiﬁcant
genes (P⩽ 1.00E− 05) observed in the performed gene-based
analyses of rare coding variants.
These four study-wide signiﬁcant loci revealed no compelling
association signals among single point tests of common variants
in this study nor in PGC (ST2 and ST3).
Examination of common variants
The most signiﬁcant signal in our meta-analysis of common
variants was observed at rs9325032 in the PPP2R2B gene (odds
ratio = 0.81, P= 1.61E− 05). No variant reached genome-wide
signiﬁcance (Po5.00E− 08). ST3 details the top SNVs with
association P-values o1.00E− 03 in the meta-analysis. SF1 depicts
the QQ-plots.
Replication was attempted for the top three common SNVs
(ST4). No variant reached genome-wide signiﬁcance (SF2).
However, rs9325032 (PPP2R2B gene) showed a modest trend of
signiﬁcance (P= 0.033, ST4A), although signiﬁcant heterogeneity
(for example, differences in estimated MAFs) and discordant
direction of effect was observed among samples (ST4A).
Comparisons using the data for childhood ADHD collected by
the PGC26 revealed no signiﬁcant ﬁndings for the top SNVs in the
current study (ST4B).
In silico functional analyses of the signiﬁcant loci
In total, 32 rare coding SNVs contributed to the gene-based
association signals passing study-wide Bonferroni correction in the
four loci (6q22.1, SEC23IP, PSD and ZCCHC4). No single common
variant reached genome-wide signiﬁcance and, thus, common
variants were not assessed further for functionality. First, we
evaluated the effect of rare missense variants on the encoded
protein in the most signiﬁcant locus of NT5DC1. The NT5DC1
protein contains a known 5′-nucleotidase domain (aa11–337) and
a haloacid dehalogenase-like domain (aa198–324). Table 2 sum-
marizes the results of sequence alignment using protein blast and
protein homology modeling (template NP_689942.2) to assess the
severity of the observed NT5DC1 missense variants in this locus.
Structural inspection of the SNVs in the NT5DC1 locus revealed
their potential to form a possible phosphorylation site
(rs150257749) and to induce conformational change
(rs150293032) (Table 2 and SF3B), both of which may inﬂuence
the function of the protein. A homology model of human NT5DC1
and structural inspection of the three missense mutation sites in
human NT5DC1 are presented in SF3. The NT5DC1 sequence
alignment is shown in SF4.
While examining the impact on their respective encoded
proteins across all the 32 variants, six were predicted to be
deleterious by both PolyPhen and SIFT: one in NT5DC1
(rs150293032), two in PSD (rs142273937 and rs200819772), two
in SEC23IP (rs142665854 and rs142266445) and one in ZCCHC4
(rs151252286). Detailed features of these missense variants are
presented in ST5.
Apart from surveying the possible direct effects of the variants
on their encoded proteins, we also explored their regulatory
potential using RegulomeDB. These analyses revealed that the
SNVs with the most likely regulatory effect reside within the PSD
gene (rs147203944, rs148732359 and rs142273937) and probably
affect the binding properties of polymerase (RNA) II (DNA
directed) polypeptide A (POLR2A) as well as may alter CTCF
regulatory element binding (rs140739855 and rs200819772) (ST6).
In addition, the binding of POLR2A and CTCF may also be affected
by the variants in the other two study-wide signiﬁcant loci:
rs73357833 in SEC23IP, rs201763036 in ZCCHC4 (ST6). No
signiﬁcant eQTL effects were observed. Detailed RegulomeBD
features of all variants are presented in ST6. T
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Exploration of biological pathways: GO terms
To evaluate whether certain biological processes may be
implicated by our results, we performed gene-set analyses using
GO terms. Among the GO terms, 1.844 terms contained data for 10
or more genes in our data set. This brings the Bonferroni-corrected
signiﬁcance threshold to a P-value of 2.17E− 05. The strongest
association was observed for ‘mRNA 3′-end processing
(GO:0031124 term, P= 1.07E− 04). ST7 summarizes the top GO
terms (P⩽ 1.00E− 03) observed in the meta-analysis of both
common and rare variants.
Gene expression in brain tissue
The expression of the four study-wide signiﬁcant loci (NT5DC1,
SEC23IP, PSD and ZCCHC4) was evaluated throughout life in the
Human Brain Transcriptome atlas. The transcriptional trajectories
of all four loci revealed variability between pre- and post-natal
stages, in line with the general patterns of gene expression in the
brain across the lifetime.27 Supplementary Figure 6 depicts the
expression levels of these loci throughout life.
We have also examined the expression patters of the four
aforementioned loci with regards to the brain regions. NT5DC1
revealed the highest expression in substantia nigra as well as
other midbrain and hindbrain structures (FANTOM5 and GTEx
projects, adult expression levels). The other three loci showed high
expression in the cortex and basal ganglia input nuclei (ZCCHC4,
FANTOM5 data), and throughout brain (SEC23IP, PSD, mouse data
in Allen Brain Atlas).
DISCUSSION
This study aimed to shed light to the genetic architecture of adult
ADHD, the form of this disorder that has received relatively little
attention so far. Our main ﬁndings are the novel, study-wide
signiﬁcant candidate loci for adult ADHD at 6q22.1, where NT5DC1
and COL10A1 reside, as well as the SEC23IP, PSD and ZCCHC4 loci.
NT5DC1 encodes a member of the haloacid dehalogenase
superfamily of enzymes, the exact physiological role of which is
still largely unknown.28 On the basis of its sequence similarity to
other haloacid dehalogenases, NT5DC1 may be involved in the de-
phosphorylation of intracellular signaling molecules and our in
silico analyses of the SNVs contributing to its association signal
suggest that these variants may alter its function (Table 2). The
NT5DC1 locus, however, also contains a shorter COL10A1 gene that
is embedded in reverse orientation in NT5DC1 intron 6 (SF5). With
our sample size it is not possible to statistically distinguish the
effects of these two genes from each other, but the strongest
association is seen when testing the larger NT5DC1 gene
(P= 4.48E− 08).
Similarly to 6q22.1 locus, the protein encoded by SEC23IP
belongs to a family of enzymes as well: intracellular phospholipase
A1 family that degrades phospholipids and is involved in
membrane trafﬁcking.29 Altogether with actin cytoskeleton
organization, membrane trafﬁcking is also a mechanism through
which PSD-encoded protein (a guanine nucleotide exchange
factor) mediates a number of neuronal functions,30 including
dendritic spine formation and stabilization.31 Furthermore,
ZCCHC4-encoded zinc-ﬁnger DNA-binding protein may also be
linked to cell signal transduction as suggested epigenetic silencer
of RAS gene family.32,33 RAS genes reportedly inhibit apoptosis,33 a
physiological cell death by which unsuccessful neurons are
deleted from the central nervous system in the developing
brain.34
Thus, in this study, we noted association signals in several genes
involved in signal transduction, highlighting the possible role of
cellular communication in the development of adult ADHD. In line
with these observations, previous studies have implicated all four
of our study-wide signiﬁcant loci in disorders of the central
nervous system, including ADHD and related neurodevelopmental
disorders, ADHD co-morbid conditions as well as syndromes
where ADHD symptoms are present.35–51 In addition, paralogs of
the NT5DC1 gene have also been reported to have role in the
development of ADHD and other neuropsychiatric disorders.52–54
These ﬁndings ﬁt with the higher transcript level of NT5DC1
reported in substantia nigra, a major localization of dopaminergic
neurons.
Despite being the largest genetic study on adult ADHD, it is still
likely to be underpowered to detect variants with very small effect
sizes. Thus, no genome-wide signiﬁcant signal was observed for
common polymorphisms (MAF⩾ 1%). However, gene-based sta-
tistical methods to analyze rare variants combined could
potentially improve power.55 These aggregation tests are based
on various assumptions about the underlying genetic architecture
and their power depends on the true, and, in case of ADHD,
unknown, disease model.55 In this study, we used two methods
to detect gene-based association: (1) the VT method that leans
on the view of functional allelic variants being a subject to
purifying selection pressure and empirically calculates a threshold
below which the variants are more likely to be functional, based
on the observed data; and (2) MAF-weighted burden test, which
makes the same assumption of functional variants being under
selective pressure as the VT method. As all the four study-wide
signiﬁcant loci reveal association signals with both methods
(ST1B), it may suggest that the results appear to be robust with
regard to different gene-based tests operating under the same
hypothesis and that such applications may help us in uncovering
underlying genetic architecture of such complex disorders
as ADHD.
Taken together, all four study-wide signiﬁcant loci have been
implicated in the function of neural circuitry and communication,
cellular mechanisms previously linked to the development of
mental disorders,56 including childhood ADHD.1 Thus, dysregula-
tion of cellular communication could be a core component in the
development of both adult and childhood forms of ADHD.
Nonetheless, these ﬁndings should be subjected to further
examination in larger samples before their role in ADHD can be
ﬁrmly established.
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